DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Mecasermin rinfabate
Mecasermin rinfabate
View Annual Report
Table of Contents
Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Type 1 Diabetes
Mecasermin Rinfabate for the Prevention of Retinopathy of Prematurity in Neonates of Less Than 32 Weeks of Gestational Age
(Mecasermin Rinfabate [Rdna Origin] Injection) DESCRIPTION IPLEX
Insulin-Like Growth Factor Binding Proteins: a Structural Perspective, Frontiers in Endocrinology, 2012; 3:38
(INN) for Biological and Biotechnological Substances
WO 2017/036580 Al 9 March 2017 (09.03.2017) P O P C T
Conflict of Interest Disclosures
IPLEX™ Mecasermin Rinfabate
Novel Players in Cardioprotection: Insulin Like Growth Factor-1, Angiotensin-(1–7) and Angiotensin-(1–9)
Pharmacy Medical Necessity Guidelines: Increlex ® (Mecasermin)
Longitudinal Infusion of a Complex of Insulin-Like Growth Factor- I and IG F
Receptor-Mediated Muscle Homeostasis As a Target for Sarcopenia Therapeutics
Performance Enhancement
Orphan Drug Designation List
Top View
Modifying IGF1 Activity: an Approach to Treat Endocrine Disorders, Atherosclerosis and Cancer
Mecasermin Rinfabate for the Treatment of Primary Insulin-Like Growth Factor-1 Deficiency Due to Molecular Or Genetic Defects
Anterior Pituitary Hormones Will Go to a Nonendocrine Organ (Ex
(12) Patent Application Publication (10) Pub. No.: US 2008/0066741 A1 Lemahieu Et Al
Increlex AHM
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Customs Tariff - Schedule Xxi - 1
Why Are People with Laron Syndrome Immune to Cancer? by Raquel Margolis Raquel Margolis Graduated in July 2015 with a B.S
Who Drug Information
(12) Patent Application Publication (10) Pub. No.: US 2010/0278784 A1 Pojasek Et Al
Orphan Drug Designations and Approvals List As of 12‐01‐2014
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
IPLEX-Withdrawal Assessment Report
WO 2013/148158 Al 3 October 2013 (03.10.2013) P O P C T
Interactions Pharmacokinetics Profile Uses and Administration
Title List Patient Education Text Drug Information
Novel Players in Cardioprotection: Insulin Like Growth Factor-1, Angiotensin-(1–7) and Angiotensin-(1–9)
Mecasermin Rinfabate for Severe Insulin-Like Growth Factor-I Deficiency
Treatment for Severe Primary IGF-1 Deficiency
Open-Label Trial of Recombinant Human Insulin-Like Growth Factor 1/Recombinant Human Insulin-Like Growth Factor Binding Protein 3 in Myotonic Dystrophy Type 1
WO 2 Ll/14 A2
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016